SCHEMBL13804292

SCHEMBL13804292

CCC1(C)CCN(C(C)=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP2D6 P10635 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
USP2 O75604 3/20 0.40
EPHX2 P34913 1/20 0.40
PIK3CD O00329 1/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP2C19 P33261 3/20 0.39
MAPK1 P28482 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
VNN1 O95497 1/20 0.38
CYP2C9 P11712 4/20 0.38
TSHR P16473 2/20 0.38
CYP3A4 P08684 2/20 0.37
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13819904 0.88 SMN1; SMN2 (0.39) CYP1A2TDP1CYP2D6SMN1; SMN2KDM4E
SCHEMBL13819676 0.88 SMN1; SMN2 (0.39) CYP1A2TDP1CYP2D6SMN1; SMN2KDM4E
SCHEMBL22758461 0.83 CYP1A2 (0.40) CYP1A2TDP1CYP2D6SMN1; SMN2KDM4E
SCHEMBL14417843 0.83 CYP1A2 (0.43) CYP1A2TDP1CYP2D6SMN1; SMN2KDM4E
SCHEMBL13804168 0.81 ALDH1A1 (0.48) EPHX2ALDH1A1MEN1KMT2AVNN1
SCHEMBL13819952 0.80 CYP1A2 (0.44) CYP1A2TDP1CYP2D6SMN1; SMN2KDM4E
SCHEMBL24220730 0.79 MAPT (0.45) SMN1; SMN2ALDH1A1MEN1KMT2AVNN1
SCHEMBL23329475 0.79 AOC2 (0.37) ALDH1A1KMT2AVNN1
SCHEMBL19132749 0.79 EPHX2 (0.39) CYP1A2TDP1KDM4EEPHX2PIK3CD
SCHEMBL19738853 0.78 CYP1A2 (0.43) CYP1A2TDP1CYP2D6SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023081328-A1 HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF VALO HEALTH, INC. (US) 2023-05-11 WO disclosed
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 US disclosed
US-20220023281-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2022-01-27 US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 US disclosed
WO-2020245664-A1 N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES STEP PHARMA S.A.S. (FR) 2020-12-10 WO disclosed
EP-3377060-B1 PYRAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF LUNDBECK LA JOLLA RESEARCH CENTER INC (US) 2020-08-19 EP disclosed
US-RE47334-E1 Macrocyclic inhibitors of flaviviridae viruses GILEAD SCIENCES, INC. (US) 2019-04-02 US disclosed
US-9732029-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
EP-2804868-B1 PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2017-04-12 EP disclosed
WO-2016191172-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2016-12-01 WO disclosed
WO-2009070485-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE CYP2C19, CYP4A11, CYP11B1 CYP1A2 26/4885TDP1 4253/4885CYP2D6 75/4885
US-11365192-B2 Pyridine compound substituted with azole CYP2C19, CYP4A11, CYP11B1 CYP1A2 26/4885TDP1 4253/4885CYP2D6 75/4885
US-20220023281-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS MC2R, AGTR2, AGTR1 CYP1A2 392/4885TDP1 4535/4885CYP2D6 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.